Trend — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg (Q5104) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for Q5104 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.